AUTHORS
Nickolas Steinauer, M.D., Ph.D., Ashya R Burgess, MS2, Julia Castro Weiss3, Aref Al-Kali, M.D.4, Tariq Kewan, MD5, Antoine N. Saliba, M.D.6, Kristen McCullough, PharmD7, Kaaren Reichard, MD8, Terra Lasho, PhD9, Christy Finke, BS10, Pankaj Pradeep11, Jenna Fernandez, Ph.D.12, Ryan Carr, MD, PhD13, Martin Fernandez-Zapico, MD14, Erik Asmus15, Susan Geyer, PhD16, Abhishek Avinash Mangaonkar, MBBS17, Mrinal M. Patnaik, MD, MBBS18
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
BACKGROUND: Chronic myelomonocytic leukemia (CMML) is the most common MDS/MPN overlap neoplasm and includes a myeloproliferative subtype (MP-CMML; WBC >13 × 10?/L) characterized by adverse outcomes and frequent RAS pathway mutations. We previously demonstrated that oncogenic RAS signaling promotes the MP-CMML phenotype through KMT2A-dependent upregulation of polo-like kinase 1 (PLK1), and that pharmacologic PLK1 inhibition is highly active in preclinical RAS-mutant CMML models (Carr et al. Nat Commun. 2021), establishing PLK1 as a rational therapeutic target in MP-CMML.
METHODS: We conducted an ongoing phase 1 study (NCT05549661) evaluating oral Onvansertib in patients with relapsed/refractory MP-CMML. Onvansertib was administered on days 1–21 of 28-day cycles. A Bayesian Optimal Interval dose-escalation design evaluated 6, 9, and 12 mg/m² dose levels, establishing 12 mg/m² as the maximum tolerated dose and recommended expansion dose. Eligible patients had morphologically confirmed MP-CMML and were refractory, relapsed, or intolerant to hydroxyurea or ≥4 cycles of hypomethylating agent (HMA) therapy. Responses were assessed after cycle 3 according to MDS/MPN response criteria (2015).Pharmacodynamic (PD) target engagement was evaluated by measuring inhibition of TCTP serine 46 phosphorylation (TCTP-S46) in HL60 cells exposed to patient plasma collected during treatment. Patient-paired RNA seq was performed on bone marrow mononuclear cells obtained at baseline and end of cycle 3 (EOC3), and differential gene expression analysis was conducted with DESeq2 used to assess treatment-induced expression changes between these two timepoints, stratified by response status.
RESULTS: Between April 2023 and July 2026, 15 patients were enrolled, including 5 in the dose-expansion cohort: 60% male (n=9) with a median age of 73 years (range, 60–88), median hemoglobin of 10.0 g/dL (range, 7.1–14.3), and median platelet count of 65 × 109/L (range, 20–170). The most frequent pathogenic somatic mutations were SRSF2 (73%), TET2 (73%), and ASXL1 (60%), while 66% of patients harbored at least 1 RAS pathway mutation (NRAS, KRAS, CBL, NF1, or PTPN11). Thirteen (86%) patients were refractory/intolerant to hydroxyurea, while 2 (14%) were refractory to HMA. Among 15 evaluable patients, the overall response rate (ORR) was 33% (5/15), including 2 patients achieving an optimal marrow response (13%) and 3 patients experiencing clinical benefit (20%; 1 spleen volume response, 1 erythroid & platelet response and 1 total symptom response). Six patients (40%) had stable disease, while 4 (27%) experienced disease progression. We did not observe a differential freqeuncy of RAS pathway mutations between responders (3/5) and non-responders (7/10). No dose-limiting toxicities were observed. Seven patients (47%) experienced a grade ≥3 adverse event considered at least possibly related to Onvansertib. PD studies confirmed on-target PLK1 inhibition, as plasma collected during treatment reduced TCTP-S46 ex vivo, demonstrating biologically active drug concentrations sufficient to inhibit PLK1 signaling. Baseline and EOC3 RNA-Seq samples were available for 10 patients, including 3 responders and 6 non-responders. Responders demonstrated treatment-induced activation of TP53 target programs together with suppression of hematopoietic stem cell (HSC) and G2/M cell-cycle signatures. In contrast, non-responders exhibited persistent enrichment of HSC-associated transcriptional programs, suggesting maintenance of stem-cell programs as a potential mechanism of resistance.
CONCLUSIONS: Onvansertib demonstrated acceptable safety, pharmacodynamic target engagement, and encouraging clinical activity in relapsed/refractory MP-CMML. Treatment response was associated with activation of TP53 programs and suppression of HSC-associated transcription, whereas persistence of stem-cell signatures identified a potential mechanism of resistance. These findings provide a biologic rationale for biomarker-driven evaluation of PLK1 inhibition in CMML.
DISCLOSURES
Nickolas Steinauer, M.D., Ph.D.: No relevant conflicts of interest to declare.